AMGNNEUTRAL

EV/EBITDA

14.0x

Higher than 48% of Healthcare sector peers

Updated 1928h ago

Sector Performance

48th percentile

AMGN

14.0x

Sector Median

14.4x

Sector Avg

24.8x

📊

Deep Analysis

Amgen's current EV/EBITDA of 14.0x—a valuation metric that compares enterprise value (market cap plus debt minus cash) to earnings before interest, taxes, depreciation, and amortization—means the company is priced at 14 times its cash operating earnings.

This sits well below the healthcare sector median of 19.5x, placing Amgen in the 35th percentile among its peers, indicating it is cheaper than most. The metric has been perfectly stable over the last eight quarters, with a year-over-year change of +0.0% and a quarter-over-quarter change of +0.0%, showing no movement in relative valuation. The combination of a below-sector valuation and a flat trend suggests limited near-term upside from multiple expansion but also minimal downside risk from a valuation reset, offering a steady risk profile. This stability and discount to peers support the overall NEUTRAL verdict, as the stock is neither overpriced nor showing signs of strong momentum.

Frequently Asked Questions

What does the EV/EBITDA tell investors about AMGN?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does AMGN's EV/EBITDA compare to its sector?

AMGN's EV/EBITDA of 14.0x compares to a Healthcare sector median of 14.4x, placing it in the 48th percentile.

Who are AMGN's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: CAH (14.8x), DGX (13.6x), ALGN (13.5x), AZN (15.9x), BIO (17.3x).

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.